CN103142547A - Calcitriol enteric capsule and preparation method thereof - Google Patents
Calcitriol enteric capsule and preparation method thereof Download PDFInfo
- Publication number
- CN103142547A CN103142547A CN2013100925741A CN201310092574A CN103142547A CN 103142547 A CN103142547 A CN 103142547A CN 2013100925741 A CN2013100925741 A CN 2013100925741A CN 201310092574 A CN201310092574 A CN 201310092574A CN 103142547 A CN103142547 A CN 103142547A
- Authority
- CN
- China
- Prior art keywords
- calcitriol
- core
- enteric
- coated capsule
- enteric coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a calcitriol enteric capsule and a preparation method thereof. The enteric capsule consists of a core and an enteric coating layer, wherein the enteric coating layer contains an enteric material accounting for 10-20% by weight, and the core is prepared from the following ingredients in percentage by weight: 0.0005% of calcitriol, 2.0-4.0% of meglumine, 1.2-1.8% of polyethylene glycol 400, 15-25% of polyethylene glycol 6000, 50.0-70.0% of filler, 5.0-10.0% of disintegrant and an appropriate amount of binder. According to the enteric capsule, the content of calcitriol is remarkably increased, so that the drug dosage is reduced; and the stability of calcitriol to light and air is improved, and the bioavailability of calcitriol is also remarkably improved.
Description
Technical field
The present invention relates to the pharmaceutical technology field, be specifically related to a kind of calcitriol enteric coated capsule and preparation method thereof.
Background technology
Calcitriol (Calcitriol) is white crystalline powder, to light and air-sensitive.Be slightly soluble in methanol, ethanol, ethyl acetate.Tm is 111-115 ℃.It is one of most important metabolic activity product of vitamin D3 in human body, has the intestinal absorption of impelling calcium and regulates in sclerotin the effect such as inorganic salt transhipment; Be mainly used in osteoporosis; The renal osteodystrophy of Patients with Chronic Renal Failure particularly needs the patient of chronic hemodialysis; After operation, spontaneity and false parathyroid gland machine go down; Vitamin D3 dependency rickets and hypophosphatemia vitamin D resistance rickets; The dermatosiss such as psoriasis; And other vitamin D deficiencies.The oral absorption of calcitriol is fast, reaches the peak in 3～6 hours, t1/2 approximately 3～6 hours, and the urine calcium concentration increases after 7 hours, the sustainable pharmacologically active of single oral dose 3～5 days.
At present, the main dosage form of calcitriol is soft capsule and soft gelatin capsule; Dosage form is more dull, and calcitriol is lower for the ordinary organic solvents dissolubility to light and air-sensitive, soft capsule and soft gelatin capsule stable bad, and active constituent content is extremely low, and bioavailability is low.The calcitriol enteric coated capsule does not have report in the prior art, and reason is that it can not steady in a long-termly exist, and bioavailability is not high.
Summary of the invention
Research worker is unexpected to be found, during preparation calcitriol enteric coated capsule, the meglumine that adds in right amount, PEG400 and polyethylene glycol 6000, can significantly improve content, stability and the bioavailability of calcitriol in preparation, have unforeseeable technique effect, significant for the clinical use of medicine.
The invention provides the calcitriol enteric coated capsule that a kind of active component content is high, medicine stability good, bioavailability is high.This enteric coated capsule is comprised of core core and enteric coat layer, and wherein enteric coat layer comprises the enteric material that percentage by weight is 10-20%, and the core core is made by the component of following percentage by weight:
In its optimizing prescriptions, to comprise percentage by weight be 15% enteric material to enteric coat layer, and the core core is made by the component of following percentage by weight:
Further, above-mentioned filler is selected from one or more in starch, lactose, dextrin, amylum pregelatinisatum and Icing Sugar.
Further, above-mentioned disintegrating agent is selected from one or more in carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose and sodium alginate.
Further, above-mentioned binding agent is selected from one or more in starch, pregelatinized Starch, hyprolose, hypromellose and polyvidone.
Further, above-mentioned enteric material is selected from one or more in CAP, methacrylic acid copolymer, cellulose acetate benzenetricarboxylic acid ester and hydroxypropyl cellulose phthalate ester.
The preparation method of this enteric coated capsule is:
1) take the supplementary material of recipe quantity, cross respectively the 80-120 mesh sieve standby;
2) binding agent and the enteric material got after sieving add respectively distilled water, make binder solution and coating solution;
3) calcitriol, meglumine, PEG400, polyethylene glycol 6000, filler and the disintegrating agent after sieving by equivalent incremental method mix homogeneously, adds above-mentioned binder solution to make soft material;
4) granulate with 40 mesh sieves after, dry 30-60min under 50-70 ℃ crosses 20 mesh sieve granulate; Remove fine powder after No. 4 sieve sieves, make the core core;
5) with above-mentioned coating solution, the core core that makes is carried out fluidized bed coating, drying is in the capsulae vacuus of packing into and get final product.
The preparation method of this enteric coated capsule is more preferably:
1) take the supplementary material of recipe quantity, cross respectively 100 mesh sieves standby;
2) binding agent and the enteric material got after sieving add respectively distilled water, make binder solution and coating solution;
3) calcitriol, meglumine, PEG400, polyethylene glycol 6000, filler and the disintegrating agent after sieving by equivalent incremental method mix homogeneously, adds above-mentioned binder solution to make soft material;
4) granulate with 40 mesh sieves after, dry 45min under 60 ℃ crosses 20 mesh sieve granulate; Remove fine powder after No. 4 sieve sieves, make the core core;
5) with above-mentioned coating solution, the core core that makes is carried out fluidized bed coating, drying is in the capsulae vacuus of packing into and get final product.
The invention has the beneficial effects as follows:
1. in said preparation, the content of calcitriol significantly increases, and has reduced the dose of medicine;
2. improved the stability of calcitriol to light, air having added of meglumine, PEG400 and polyethylene glycol 6000, its bioavailability is also significantly improved.
The specific embodiment
Below in conjunction with concrete embodiment, technical scheme of the present invention is further described.
Embodiment 1 calcitriol enteric coated capsule
Prescription is:
The core core is made by the component of following percentage by weight:
It is 10% CAP that enteric coat layer comprises percentage by weight.
Preparation method is:
1) take the supplementary material of recipe quantity, cross respectively 80 mesh sieves standby;
2) starch and the CAP got after sieving add respectively distilled water, make binder solution and coating solution;
3) calcitriol, meglumine, PEG400, polyethylene glycol 6000, starch and the carboxymethyl starch sodium after sieving by equivalent incremental method mix homogeneously, adds above-mentioned binder solution to make soft material;
4) granulate with 40 mesh sieves after, dry 30min under 50 ℃ crosses 20 mesh sieve granulate; Remove fine powder after No. 4 sieve sieves, make the core core;
5) with above-mentioned coating solution, the core core that makes is carried out fluidized bed coating, drying is in the capsulae vacuus of packing into and get final product.
Embodiment 2 calcitriol enteric coated capsulees
Prescription is:
The core core is made by the component of following percentage by weight:
It is 20% cellulose acetate benzenetricarboxylic acid ester that enteric coat layer comprises percentage by weight.
Preparation method is:
1) take the supplementary material of recipe quantity, cross respectively 120 mesh sieves standby;
2) pregelatinized Starch and the cellulose acetate benzenetricarboxylic acid ester got after sieving add respectively distilled water, make binder solution and coating solution;
3) calcitriol, meglumine, PEG400, polyethylene glycol 6000, lactose and the low-substituted hydroxypropyl cellulose after sieving by equivalent incremental method mix homogeneously, adds above-mentioned binder solution to make soft material;
4) granulate with 40 mesh sieves after, dry 60min under 70 ℃ crosses 20 mesh sieve granulate; Remove fine powder after No. 4 sieve sieves, make the core core;
5) with above-mentioned coating solution, the core core that makes is carried out fluidized bed coating, drying is in the capsulae vacuus of packing into and get final product.
Embodiment 3 calcitriol enteric coated capsulees
Prescription is:
The core core is made by the component of following percentage by weight:
It is 15% hydroxypropyl cellulose phthalate ester that enteric coat layer comprises percentage by weight.
Preparation method is:
1) take the supplementary material of recipe quantity, cross respectively 100 mesh sieves standby;
2) polyvidone and the hydroxypropyl cellulose phthalate ester got after sieving add respectively distilled water, make binder solution and coating solution;
3) calcitriol, meglumine, PEG400, polyethylene glycol 6000, dextrin and the microcrystalline Cellulose after sieving by equivalent incremental method mix homogeneously, adds above-mentioned binder solution to make soft material;
4) granulate with 40 mesh sieves after, dry 45min under 60 ℃ crosses 20 mesh sieve granulate; Remove fine powder after No. 4 sieve sieves, make the core core;
5) with above-mentioned coating solution, the core core that makes is carried out fluidized bed coating, in the capsulae vacuus of packing into and get final product.
Comparing embodiment 1 calcitriol enteric coated capsule
The core core is made by the component of following percentage by weight:
It is 15% hydroxypropyl cellulose phthalate ester that enteric coat layer comprises percentage by weight.
Preparation method is with embodiment 3:
Comparing embodiment 2 calcitriol enteric coated capsulees
The core core is made by the component of following percentage by weight:
It is 15% hydroxypropyl cellulose phthalate ester that enteric coat layer comprises percentage by weight.
Preparation method is with embodiment 3.
Comparing embodiment 3 calcitriol enteric coated capsulees
The core core is made by the component of following percentage by weight:
It is 15% hydroxypropyl cellulose phthalate ester that enteric coat layer comprises percentage by weight.
Preparation method is with embodiment 3.
Embodiment 4 stability experiments and result
1. accelerated stability test
Intensity of illumination 4500lx regularly adopted the HPLC method to carry out assay after sampling in the 0th, 5 and 10 day.
The condition of HPLC is: chromatographic column: the ODS-C18 post, take octadecylsilane chemically bonded silica as filler; Mobile phase: acetonitrile-water (75:25); Detect wavelength: 265nm; Flow velocity: 1.0mL/min; Sample size: 50 μ L.Theoretical cam curve is pressed calcitriol peak calculating and should do not hanged down 5000, and calcitriol peak and the peak-to-peak separating degree of trans calcitriol should be greater than 1.0.Adopt external standard method to calculate content.Assay result (percentage ratio of the amount of recording and labelled amount) sees the following form 1.Result shows that the stability of active component calcitriol in calcitriol enteric coated capsule of the present invention obviously is better than the comparative example.
Table 1 accelerated stability test assay result (%)
2. long-term stable experiment
25 ℃ of temperature, relative humidity were placed 36 months for 60% time, respectively at 0,3,6,12,24 and 36 months the time sampling adopt the HPLC method to carry out assay.The same accelerated stability test of the condition of HPLC.Adopt external standard method to calculate content.Assay result (percentage ratio of the amount of recording and labelled amount) sees the following form 2.Result shows that the stability of active component calcitriol in calcitriol enteric coated capsule of the present invention obviously is better than the comparative example.
Table 2 long-term stable experiment assay result (%)
The comparative test of embodiment 5 bioavailability
4 beasle dogs (being male) are carried out oral administration, feed respectively the calcitriol enteric coated capsule with the embodiment of the present invention 3, comparative example 1, comparative example 2, comparative example 3 (25 ℃ of temperature, relative humidity were placed 12 months for 60% time) to them, dosage is 10.0 μ g/ only (in calcitriol), and be 7 days the interval time of each administration.After giving medicine, blood sample collection under different time, and carry out the maximum haemoconcentration (C of calcitriol
max) and bioavailability (AUC
0 → 48) calculating.Acquisition time is 0h, 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 32h, 48h.
Following table 3 provides the average result that 4 beasle dogs is given the embodiment of the present invention 3, comparative example 1, comparative example 2, comparative example's 3 calcitriol enteric coated capsule gained.As seen from table, the maximum haemoconcentration of the calcitriol of calcitriol enteric coated capsule of the present invention (embodiment 3) and bioavailability are apparently higher than the comparative example.
The comparison of table 3 bioavailability (10.0 μ g, n=3)
Should be noted that; the above is only preferred embodiment of the present invention; be not limited to scope of the present invention, every any modification of having done within the spirit and principles in the present invention, the replacement that is equal to and improvement etc. are within all should being included in protection scope of the present invention.
Claims (8)
1. a calcitriol enteric coated capsule, is characterized in that, this enteric coated capsule is comprised of core core and enteric coat layer, and wherein enteric coat layer comprises the enteric material that percentage by weight is 10-20%, and the core core is made by the component of following percentage by weight:
2. calcitriol enteric coated capsule according to claim 1, is characterized in that, it is 15% enteric material that described enteric coat layer comprises percentage by weight, and described core core is made by the component of following percentage by weight:
3. calcitriol enteric coated capsule according to claim 1 and 2, is characterized in that, described filler is selected from one or more in starch, lactose, dextrin, amylum pregelatinisatum and Icing Sugar.
4. calcitriol enteric coated capsule according to claim 1 and 2, is characterized in that, described disintegrating agent is selected from one or more in carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose and sodium alginate.
5. calcitriol enteric coated capsule according to claim 1 and 2, is characterized in that, described binding agent is selected from one or more in starch, pregelatinized Starch, hyprolose, hypromellose and polyvidone.
6. calcitriol enteric coated capsule according to claim 1 and 2, is characterized in that, described enteric material is selected from one or more in CAP, methacrylic acid copolymer, cellulose acetate benzenetricarboxylic acid ester and hydroxypropyl cellulose phthalate ester.
7. the preparation method of the described calcitriol enteric coated capsule of claim 1-6, is characterized in that, the method comprises the steps:
1) take the supplementary material of recipe quantity, cross respectively the 80-120 mesh sieve standby;
2) binding agent and the enteric material got after sieving add respectively distilled water, make binder solution and coating solution;
3) calcitriol, meglumine, PEG400, polyethylene glycol 6000, filler and the disintegrating agent after sieving by equivalent incremental method mix homogeneously, adds above-mentioned binder solution to make soft material;
4) granulate with 40 mesh sieves after, dry 30-60min under 50-70 ℃ crosses 20 mesh sieve granulate; Remove fine powder after No. 4 sieve sieves, make the core core;
5) with above-mentioned coating solution, the core core that makes is carried out fluidized bed coating, drying is in the capsulae vacuus of packing into and get final product.
8. the preparation method of calcitriol enteric coated capsule claimed in claim 7, is characterized in that, the method comprises the steps:
1) take the supplementary material of recipe quantity, cross respectively 100 mesh sieves standby;
2) binding agent and the enteric material got after sieving add respectively distilled water, make binder solution and coating solution;
3) calcitriol, meglumine, PEG400, polyethylene glycol 6000, filler and the disintegrating agent after sieving by equivalent incremental method mix homogeneously, adds above-mentioned binder solution to make soft material;
4) granulate with 40 mesh sieves after, dry 45min under 60 ℃ crosses 20 mesh sieve granulate; Remove fine powder after No. 4 sieve sieves, make the core core;
5) with above-mentioned coating solution, the core core that makes is carried out fluidized bed coating, in the capsulae vacuus of packing into and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310092574.1A CN103142547B (en) | 2013-03-21 | 2013-03-21 | Calcitriol enteric capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310092574.1A CN103142547B (en) | 2013-03-21 | 2013-03-21 | Calcitriol enteric capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103142547A true CN103142547A (en) | 2013-06-12 |
| CN103142547B CN103142547B (en) | 2014-07-23 |
Family
ID=48541063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310092574.1A Active CN103142547B (en) | 2013-03-21 | 2013-03-21 | Calcitriol enteric capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142547B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362151A (en) * | 2017-08-01 | 2017-11-21 | 国药集团川抗制药有限公司 | A kind of calcitriol liquid hard capsule and preparation method thereof, application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101141966A (en) * | 2005-03-23 | 2008-03-12 | 拜奥克塞尔有限公司 | Use of vitamin D compounds to treat endometriosis |
| CN101554372B (en) * | 2009-05-20 | 2011-07-20 | 青岛正大海尔制药有限公司 | Calcitriol dripping pill and preparation method thereof |
-
2013
- 2013-03-21 CN CN201310092574.1A patent/CN103142547B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101141966A (en) * | 2005-03-23 | 2008-03-12 | 拜奥克塞尔有限公司 | Use of vitamin D compounds to treat endometriosis |
| CN101554372B (en) * | 2009-05-20 | 2011-07-20 | 青岛正大海尔制药有限公司 | Calcitriol dripping pill and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 朱园园等: "骨化三醇联合钙对老年性骨质疏松防治效果的研究", 《中国现代医生》 * |
| 李季等: "骨化三醇软胶囊的稳定性研究", 《中国药业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362151A (en) * | 2017-08-01 | 2017-11-21 | 国药集团川抗制药有限公司 | A kind of calcitriol liquid hard capsule and preparation method thereof, application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103142547B (en) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103142524B (en) | Calcitriol tablet and preparation method thereof | |
| CN103142470B (en) | Calcitriol injection and preparation method thereof | |
| CN103142471B (en) | Calcitriol solution and preparation method thereof | |
| CN103142554B (en) | Calcitriol controlled-release capsule and preparation method thereof | |
| CN103142501B (en) | Calcitriol pellet and preparation method thereof | |
| CN103142534B (en) | Calcitriol controlled-release tablet and preparation method thereof | |
| CN103142478B (en) | Calcitriol emulsion and preparation method thereof | |
| CN103142547B (en) | Calcitriol enteric capsule and preparation method thereof | |
| CN103142536B (en) | Calcitriol enteric tablet and preparation method thereof | |
| CN103142496B (en) | Calcitriol controlled-release granule and preparation method thereof | |
| CN103142546B (en) | Calcitriol capsule and preparation method thereof | |
| CN103142498B (en) | Calcitriol enteric granule and preparation method thereof | |
| CN103142623B (en) | Calcitriol and strontium ranelate suspension granule and preparation method thereof | |
| CN103142495B (en) | Calcitriol suspension granule and preparation method thereof | |
| CN103585357B (en) | Callicarpa nudiflora slow and its preparation method and application | |
| CN103142486B (en) | Calcitriol powder and preparation method thereof | |
| CN106265556A (en) | A kind of doxercalciferol sheet and preparation method thereof | |
| CN103142644B (en) | Calcitriol and sodium fluoride suspension granule and preparation method thereof | |
| CN104739793B (en) | A kind of Alfacalcidol piece and preparation method thereof | |
| CN103142642B (en) | Calcitriol and calcium carbonate suspension granule and preparation method thereof | |
| CN103142476B (en) | Calcitriol suspension and preparation method thereof | |
| CN104800166A (en) | Alfacalcidol powder and preparation method thereof | |
| CN103142467B (en) | Calcitriol ointment and preparation method thereof | |
| CN105287426A (en) | Doxercalciferol enteric-coated tablet and preparation method thereof | |
| CN103142466B (en) | Calcitriol gel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 266103 Qingdao economic and Technological Development Zone, unity Road, No. 3601, Shandong Applicant after: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. Address before: 266103 Haier Road, Shandong, Qingdao, No. 1 Applicant before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee after: Zhengda Pharmaceutical (Qingdao) Co., Ltd. Address before: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |